The present invention is directed to a compound of Formula (I):
or a form thereof, wherein X
1
, X
2
, X
3
, X
4
, R
1
, R
2
and R
3
are as defined herein, useful as tryptase inhibitors.
The present invention is directed to a compound of Formula (I):
or a form thereof, wherein X
1
, X
2
, X
3
, X
4
, R
1
, R
2
and R
3
are as defined herein, useful as tryptase inhibitors.
Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives
作者:Michael J. Costanzo、Stephen C. Yabut、Han-Cheng Zhang、Kimberley B. White、Lawrence de Garavilla、Yuanping Wang、Lisa K. Minor、Brett A. Tounge、Alexander N. Barnakov、Frank Lewandowski、Cynthia Milligan、John C. Spurlino、William M. Abraham、Victoria Boswell-Smith、Clive P. Page、Bruce E. Maryanoff
DOI:10.1016/j.bmcl.2008.01.093
日期:2008.3
We have explored a series of spirocyclic piperidine amide derivatives ( 5) as tryptase inhibitors. Thus, 4 (JNJ-27390467) was identified as a potent, selective tryptase inhibitor with oral efficacy in two animal models of airway inflammation ( sheep and guinea pig asthma models). An X-ray co-crystal structure of 4 tryptase revealed a hydrophobic pocket in the enzyme's active site, which is induced by the phenylethynyl group and is comprised of amino acid residues from two different monomers of the tetrameric protein. (c) 2008 Elsevier Ltd. All rights reserved.
REGULATED BIOCIRCUIT SYSTEMS
申请人:Obsidian Therapeutics, Inc.
公开号:US20190192691A1
公开(公告)日:2019-06-27
The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.